Affordable Access

Access to the full text

A feasibility study of the Nativis Voyager ® device in patients with recurrent glioblastoma in Australia

Authors
  • Murphy, Michael1, 2, 1, 2
  • Dowling, Anthony3, 4, 3, 4
  • Thien, Christopher1, 1
  • Priest, Emma1, 1
  • Morgan Murray, Donna5, 5
  • Kesari, Santosh6, 6
  • 1 Department of Neurosurgery, St Vincent's Hospital, Fitzroy, Australia
  • 2 Department of Surgery, The University of Melbourne, Parkville, Australia
  • 3 Department of Oncology, St Vincent's Hospital, Fitzroy, Australia
  • 4 Department of Medicine, The University of Melbourne, Parkville, Australia
  • 5 Nativis, Inc., Department of Clinical and Regulatory Affairs, Seattle, WA 98109, USA
  • 6 John Wayne Cancer Institute & Pacific Neuroscience Institute, Department of Translational Neurooncology and Neurotherapeutics, Santa Monica, CA, 90404, USA
Type
Published Article
Journal
CNS Oncology
Publisher
Future Medicine
Publication Date
Feb 07, 2019
Volume
8
Issue
1
Identifiers
DOI: 10.2217/cns-2018-0017
PMID: 30727742
PMCID: PMC6499017
Source
PubMed Central
Keywords
License
Green

Abstract

Aim: Evaluation of the Nativis Voyager®, an investigational medical device, as monotherapy for recurrent glioblastoma (rGBM). Materials & methods: A total of 15 patients with rGBM were treated with one of two Voyager ultra-low radio frequency energy cognates: A1A or A2HU. Safety and clinical utility were assessed every 2–4 months. Results: Median overall survival was 8.04 months in the A1A arm and 6.89 months in the A2HU arm. No serious adverse events associated with Voyager were reported. No clinically relevant trends were noted in clinical laboratory parameters or physical exams. Conclusion: The data suggest that the Voyager is safe and feasible for the treatment of rGBM.

Report this publication

Statistics

Seen <100 times